Literature DB >> 3087737

Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells.

G D Lewis, W B Campbell, A R Johnson.   

Abstract

The vasodilator prostaglandins (PGs), prostacyclin (PGI2) and PGE2, may contribute to the inflammatory response. Because glucocorticosteroids reduce inflammation, possibly through inhibition of arachidonic acid release, we examined the influence of dexamethasone on PG formation in cultures of human endothelial cells. Binding of [3H]dexamethasone by intact cells was competed by unlabeled steroids and was half-maximal at 1.2 X 10(-8) M. A cytosolic fraction complexed with [3H]dexamethasone and migrated on sucrose density gradient centrifugation with a sedimentation coefficient of 8S. 3H-steroid binding was diminished by unlabeled steroid. Histamine, bradykinin, and the ionophore, A23187, stimulated release of PGI2 and PGE2 to as much as 25 times basal release. Dexamethasone (10(-11) to 10(-7) M) reduced PG formation in cells that were stimulated by histamine, bradykinin, calcium ionophore, or mechanical agitation. The inhibitory effect required at least 4 h to develop, was maximal at 24 h, and persisted after the steroid was removed. Hydrocortisone and triamcinolone had similar effects but were less potent than dexamethasone. Testosterone and progesterone did not affect PG generation. Both arachidonic acid and PGH2 augmented formation of PGs but were not inhibited by dexamethasone. Cortisol-21-mesylate, an antagonist of glucocorticoid receptors, blocked the effects of dexamethasone on PG formation, as did treatment of the cells with cycloheximide. We conclude that glucocorticoids inhibit PG production in endothelial cells by interaction with specific steroid receptors. The steroid-mediated inhibitory effect occurs at the level of arachidonic acid release and depends upon protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087737     DOI: 10.1210/endo-119-1-62

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

1.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  The role of bradykinin in the etiology of vasogenic brain edema and perilesional brain dysfunction.

Authors:  I R Whittle; I R Piper; J D Miller
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

3.  Rapid non-genomic inhibition of ATP-induced Cl- secretion by dexamethasone in human bronchial epithelium.

Authors:  V Urbach; D E Walsh; B Mainprice; J Bousquet; B J Harvey
Journal:  J Physiol       Date:  2002-12-15       Impact factor: 5.182

4.  The contribution of arachidonic acid to the aetiology and pathophysiology of focal brain oedema; studies using an infusion oedema model.

Authors:  I R Whittle; I R Piper; J D Miller
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

5.  Glucocorticoids regulate prostacyclin synthesis and response to lipopolysaccharide in the rat aorta.

Authors:  A Danon; G Prajgrod
Journal:  Agents Actions       Date:  1991-11

Review 6.  Corticosteroids: do they damage the cardiovascular system?

Authors:  S R Maxwell; R J Moots; M J Kendall
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

7.  Biphasic regulation by dexamethasone of IL-1- and LPS-stimulated endothelial prostacyclin production.

Authors:  G Prajgrod; A Danon
Journal:  Agents Actions       Date:  1992-03

8.  Use of triamcinolone during vitrectomy surgery to visualize membranes and vitreous.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2008-12

9.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Increased lipid peroxide level and myeloperoxidase activity in the vitreous of patients suffering from proliferative vitreoretinopathy.

Authors:  T Böker; A J Augustin; W Breipohl; M Spitznas; J Lutz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.